Sökning: id:"swepub:oai:DiVA.org:kth-311786"
> (2022) >
Covid-19 in patient...
Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
-
- Blixt, L. (författare)
- Karolinska Institutet
-
Bogdanovic, G. (författare)
-
- Buggert, M. (författare)
- Karolinska Institutet
-
visa fler...
-
- Gao, Y. (författare)
- Karolinska Institutet
-
- Hober, Sophia, Professor, 1965- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi
-
Healy, K. (författare)
-
- Johansson, H. (författare)
- Karolinska Institutet
-
- Kjellander, C. (författare)
- Karolinska Institutet
-
- Mravinacová, Sára (författare)
- Karolinska Institutet,KTH,Proteinvetenskap,Science for Life Laboratory, SciLifeLab
-
- Muschiol, S. (författare)
- Karolinska Institutet
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik
-
- Palma, M. (författare)
- Karolinska Institutet
-
- Pin, Elisa (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab
-
- Smith, C. I. E. (författare)
- Karolinska Institutet
-
Stromberg, O. (författare)
-
Sällberg Chen, M. (författare)
-
- Zain, R. (författare)
- Karolinska Institutet
-
Hansson, L. (författare)
-
- Österborg, A. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2021-09-25
- 2022
- Engelska.
-
Ingår i: Leukemia. - : Springer Nature. - 0887-6924 .- 1476-5551. ; 36:2, s. 476-481
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://www.nature.c...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 y, range 43–97) were identified. Median CIRS was eight (4–20). Patients had indolent CLL (n = 38), had completed (n = 12) or ongoing therapy (n = 10). Forty-six patients (77%) were hospitalized due to severe Covid-19 and 11 were admitted to ICU. Severe Covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except CIRS (p < 0.05). Fourteen patients (23%) died; age ≥75 y was the only significant risk factor (p < 0.05, multivariate analysis with limited power). Comparing month 1–6 vs 7–13 of the pandemic, deaths were numerically reduced from 32% to 18%, ICU admission from 37% to 15% whereas hospitalizations remained frequent (86% vs 71%). Seroconversion occurred in 33/40 patients (82%) and anti-SARS-CoV-2 antibodies were detectable at six and 12 months in 17/22 and 8/11 patients, respectively. Most (13/17) had neutralizing antibodies and 19/28 had antibodies in saliva. SARS-CoV-2-specific T-cells (ELISpot) were detected in 14/17 patients. Covid-19 continued to result in high admission even among consecutive and young early- stage CLL patients. A robust and durable B and/or T cell immunity was observed in most convalescents.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- anticoagulant agent
- antineoplastic monoclonal antibody
- bendamustine
- Bruton tyrosine kinase inhibitor
- corticosteroid
- gamma interferon
- hydroxychloroquine
- hypertensive agent
- immunoglobulin
- immunoglobulin G antibody
- neutralizing antibody
- remdesivir
- rituximab
- SARS-CoV-2 antibody
- SARS-CoV-2 convalescent plasma
- tocilizumab
- venetoclax
- virus antibody
- adult
- aged
- antibody response
- Article
- body mass
- cellular immunity
- chronic lymphatic leukemia
- controlled study
- coronavirus disease 2019
- Cumulative Illness Rating Scale
- enzyme linked immunospot assay
- female
- hospitalization
- human
- humoral immunity
- intensive care
- major clinical study
- male
- mortality rate
- seroconversion
- Sweden
- B lymphocyte
- blood
- complication
- follow up
- immunology
- isolation and purification
- middle aged
- multimodality cancer therapy
- prognosis
- T lymphocyte
- very elderly
- virology
- Aged
- 80 and over
- Antibodies
- Neutralizing
- Antibodies
- Viral
- B-Lymphocytes
- Combined Modality Therapy
- COVID-19
- Follow-Up Studies
- Humans
- Leukemia
- Lymphocytic
- Chronic
- B-Cell
- SARS-CoV-2
- T-Lymphocytes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Leukemia
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Blixt, L.
-
Bogdanovic, G.
-
Buggert, M.
-
Gao, Y.
-
Hober, Sophia, P ...
-
Healy, K.
-
visa fler...
-
Johansson, H.
-
Kjellander, C.
-
Mravinacová, Sár ...
-
Muschiol, S.
-
Nilsson, Peter
-
Palma, M.
-
Pin, Elisa
-
Smith, C. I. E.
-
Stromberg, O.
-
Sällberg Chen, M ...
-
Zain, R.
-
Hansson, L.
-
Österborg, A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Leukemia
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet